 |
PDBsum entry 3phx
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/protein binding
|
PDB id
|
|
|
|
3phx
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Molecular basis for ubiquitin and isg15 cross-Reactivity in viral ovarian tumor domains.
|
 |
|
Authors
|
 |
M.Akutsu,
Y.Ye,
S.Virdee,
J.W.Chin,
D.Komander.
|
 |
|
Ref.
|
 |
Proc Natl Acad Sci U S A, 2011,
108,
2228-2233.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Crimean Congo hemorrhagic fever virus (CCHFV) is a deadly human pathogen that
evades innate immune responses by efficiently interfering with antiviral
signaling pathways mediated by NF-κB, IRF3, and IFNα/β. These pathways rely
on protein ubiquitination for their activation, and one outcome is the
modification of proteins with the ubiquitin (Ub)-like modifier
interferon-stimulated gene (ISG)15. CCHFV and related viruses encode a
deubiquitinase (DUB) of the ovarian tumor (OTU) family, which unlike eukaryotic
OTU DUBs also targets ISG15 modifications. Here we characterized the viral OTU
domain of CCHFV (vOTU) biochemically and structurally, revealing that it
hydrolyzes four out of six tested Ub linkages, but lacks activity against linear
and K29-linked Ub chains. vOTU cleaved Ub and ISG15 with similar kinetics, and
we were able to understand vOTU cross-reactivity at the molecular level from
crystal structures of vOTU in complex with Ub and ISG15. An N-terminal extension
in vOTU not present in eukaryotic OTU binds to the hydrophobic Ile44 patch of
Ub, which results in a dramatically different Ub orientation compared to a
eukaryotic OTU-Ub complex. The C-terminal Ub-like fold of ISG15 (ISG15-C) adopts
an equivalent binding orientation. Interestingly, ISG15-C contains an additional
second hydrophobic surface that is specifically contacted by vOTU. These subtle
differences in Ub/ISG15 binding allowed the design of vOTU variants specific for
either Ub or ISG15, which will be useful tools to understand the relative
contribution of ubiquitination vs. ISGylation in viral infection. Furthermore,
the crystal structures will allow structure-based design of antiviral agents
targeting this enzyme.
|
 |
|
|
|
|
 |